What this is
- How it works
- How it works isn't classified yet
- Tested for
- Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Sarcoidosis Associated Pulmonary Hypertension
- Main trialPhase 2
- “A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD).”In the company’s words, NCT05798923 on ClinicalTrials.gov
Other drugs for Pulmonary Hypertension Due to Lung Diseases and Hypoxia
- RLS-0071ReAlta Life Sciences, Inc. · Phase 2/3
- SovateltidePharmazz, Inc. · Phase 2
- CenthaquinePharmazz, Inc. · Phase 2
- TirapazamineTeclison Ltd. · Phase 1/2
Coming up2
- Mar 2028Phase 2 trial completes · ClinicalTrials.gov
- Dec 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Mar 2028 | LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | |
| Phase 2Not yet recruiting | Dec 2028 | LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026